Wound Management Technologies signs sales agreement with Med Pro Associates

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today an agreement with Med Pro Associates of Colorado to serve as a non-exclusive independent sales and marketing representative to solicit sales, obtain orders and provide sales and marketing support for the company's line of products within the U.S.

Under the terms of the agreement, Med Pro will market and sell Wound Management Technologies' CellerateRx and other products on a non-exclusive basis throughout the U.S. The initial focus will be on Wound Management Technologies' major product, CellerateRx®, which is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first and second degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds. CellerateRx's patented collagen fragments, which are a fraction of the size of the native collagen molecules and particles found in other products, deliver the benefits of collagen to the body immediately.

Wound Management Technologies CEO Scott Haire said, "This agreement with Med Pro will enable us to offer CellerateRx and other products to hospitals and doctors' offices in all 50 states. Med Pro has a well established and effective sales and marketing network that we expect will substantially increase our sales."

Cathy Bradshaw, president of Wound Management's Wound Care Innovations subsidiary, said, "WCI is excited to have Med Pro representatives marketing CellerateRx extensively throughout the country. We continue to see great results with CellerateRx and have positive feedback from physicians. Our studies continue to support the effectiveness of CellerateRx and having the Med Pro team presenting CellerateRx will increase our exposure and increase sales."